1.Sales and profit
See section β- Actuate Therapeutics, Inc. lost $22.2M in fiscal 2025.
Actuate Therapeutics, Inc.
ACTU Nasdaq Pharmaceutical Preparations Financials FY2023βFY2025
Download report
3-page PDF: the company, its results and charts with peers.
Last close Β· Oct 23, 2026
$0.48
7.9%KIRAβs summary AI analyst
Hi! I read Actuate Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
1 to watch
2.Cash and shareholders
See section β- No open-market insider trades in the last 12 months.
Actuate Therapeutics, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$22.2M
No. It lost money last year.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$11.3M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$0.88 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Actuate Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
- Time
- Time not announced
- Covers
- Period ended Sep 30, 2026
- Expected EPS
- β$0.18
- Source
- Earnings calendar
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 14, 2026 | Q2 '26 | After the market closes | 10-Q β |
| May 14, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Mar 26, 2026 | Q4 '25 | After the market closes | 10-K β |
| Nov 13, 2025 | Q3 '25 | After the market closes | 10-Q β |
| Aug 14, 2025 | Q2 '25 | After the market closes | 10-Q β |
| May 15, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Mar 13, 2025 | Q4 '24 | After the market closes | 10-K β |
| Nov 13, 2024 | Q3 '24 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
Margins, % of revenue
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Actuate Therapeutics, Inc. lost $22.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY23
Net income β$24.7M
FY24
Net income β$27.3M
FY25
Net income β$22.2M
Net income
Q3 '23
Net income β$6.3M
Q4 '23
Net income β$7.6M
Q1 '24
Net income β$8.3M
Q2 '24
Net income β$6.6M
Q3 '24
Net income β$6.0M
Q4 '24
Net income β$6.4M
Q1 '25
Net income β$6.3M
Q2 '25
Net income β$5.9M
Q3 '25
Net income β$5.4M
Q4 '25
Net income β$4.6M
Q1 '26
Net income β$5.6M
Q2 '26
Net income β$4.9M
Diluted EPS
FY23
Diluted EPS β$17.24
FY24
Diluted EPS β$3.26
FY25
Diluted EPS β$1.06
Diluted EPS
Q3 '23
Diluted EPS β$4.31
Q4 '23
Diluted EPS β
Q1 '24
Diluted EPS β$5.40
Q2 '24
Diluted EPS β$4.20
Q3 '24
Diluted EPS β$0.55
Q4 '24
Diluted EPS $6.89
Q1 '25
Diluted EPS β$0.32
Q2 '25
Diluted EPS β$0.30
Q3 '25
Diluted EPS β$0.25
Q4 '25
Diluted EPS β$0.19
Q1 '26
Diluted EPS β$0.24
Q2 '26
Diluted EPS β$0.20
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY23
Free cash flow β
FY24
Free cash flow β
FY25
Free cash flow β
Cash from operations vs capital spending
FY23
Cash from operations β$21.6M
Capital spending β
FY24
Cash from operations β$21.8M
Capital spending β
FY25
Cash from operations β$19.2M
Capital spending β
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$5.6M
Capital spending β
Q4 '23
Cash from operations β$5.5M
Capital spending β
Q1 '24
Cash from operations β$5.2M
Capital spending β
Q2 '24
Cash from operations β$2.7M
Capital spending β
Q3 '24
Cash from operations β$9.1M
Capital spending β
Q4 '24
Cash from operations β$4.8M
Capital spending β
Q1 '25
Cash from operations β$4.6M
Capital spending β
Q2 '25
Cash from operations β$4.2M
Capital spending β
Q3 '25
Cash from operations β$6.7M
Capital spending β
Q4 '25
Cash from operations β$3.7M
Capital spending β
Q1 '26
Cash from operations β$5.0M
Capital spending β
Q2 '26
Cash from operations β$4.4M
Capital spending β
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.01B
FY25
Diluted shares 0.02B
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Actuate Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY23
Cash $3.0M
Debt β
FY24
Cash $8.6M
Debt β
FY25
Cash $13.2M
Debt β
Cash
Debt
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $3.0M | $8.6M | $13.2M |
| Interest coverage | β572.8x | β1,345.5x | β1,108.1x |
| Current ratio | 0.4x | 1.0x | 2.4x |
| Quick ratio | 0.4x | 1.0x | 2.4x |
| Total assets | $3.0M | $9.3M | $14.0M |
| Total liabilities | $8.4M | $9.2M | $6.1M |
| Shareholders' equity | β$99.6M | $0.1M | $7.9M |
| Net debt (β = net cash) | β | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY23
Return on capital β
Return on equity β
Return on assets β826.0%
FY24
Return on capital β
Return on equity β
Return on assets β443.2%
FY25
Return on capital β
Return on equity β553.7%
Return on assets β190.4%
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 |
| Accruals ratio | β104.1% | β88.4% | β25.9% |
| Altman Z'' | β191.38 | β64.16 | β41.61 |
All figures
Every number, year by year.
3 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Research and development | $21.7M | $18.7M | $10.3M |
| Operating income | β$25.0M | β$25.2M | β$22.5M |
| Interest expense | $0.0M | $0.0M | $0.0M |
| Income tax | $0.0M | $0.0M | $0.0M |
| Net income | β$24.7M | β$27.3M | β$22.2M |
| Diluted EPS | β$17.24 | β$3.26 | β$1.06 |
| Diluted shares | 0.00B | 0.01B | 0.02B |
| Cash flow | |||
| Cash from operations | β$21.6M | β$21.8M | β$19.2M |
| Stock-based compensation | $0.4M | $2.0M | $6.0M |
| Balance sheet | |||
| Cash and short-term investments | $3.0M | $8.6M | $13.2M |
| Current assets | $3.0M | $9.2M | $13.6M |
| Current liabilities | $6.9M | $8.8M | $5.7M |
| Total assets | $3.0M | $9.3M | $14.0M |
| Total liabilities | $8.4M | $9.2M | $6.1M |
| Preferred stock | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$99.6M | $0.1M | $7.9M |
| Returns | |||
| Return on capital employed | 636.3% | β4,877.0% | β270.1% |
| Return on equity | β | β | β553.7% |
| Return on assets | β826.0% | β443.2% | β190.4% |
| Return on tangible equity | β | β26,185.5% | β280.5% |
| Growth | |||
| Share count change | β | 483.5% | 151.1% |
| Financial health | |||
| Interest coverage | β572.8x | β1,345.5x | β1,108.1x |
| Current ratio | 0.4x | 1.0x | 2.4x |
| Quick ratio | 0.4x | 1.0x | 2.4x |
| Quality scores | |||
| Altman Z'' | β191.4 | β64.2 | β41.6 |
| Accruals ratio | β104.1% | β88.4% | β25.9% |
Source: SEC EDGAR XBRL filings (CIK 0001652935). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.